Bio-Sourcing Secures €12.5M in Funding to Revolutionize Biosimilar Production with BioMilk Platform

Biosimilars are essential but costly treatments that are similar to previously approved biological drugs, making them less accessible despite their critical role in healthcare.

Bio-Sourcing, a pioneering Belgian biotherapeutic company, has been awarded €12.5M in funding—€2.5M in grants and €10M in equity—from the European Innovation Council (EIC) Accelerator. This funding recognizes the transformative potential of Bio-Sourcing's innovative BioMilk™ platform, which enables large-scale production of biosimilars with five times the efficiency of traditional methods, significantly reducing costs and carbon emissions.

The €2.5M grant will be used to advance Bio-Sourcing's first biosimilar, adalimumab (Humira), to clinical trials by 2027. The €10M equity, part of the company’s next venture round, will fund these trials and support the expansion of Bio-Sourcing's facilities, including the scaling of a goat farm and the construction of an industrial milk processing plant.

Biosimilars are essential but costly treatments that are similar to previously approved biological drugs, making them less accessible despite their critical role in healthcare. Bio-Sourcing’s BioMilk platform, which uses goats to produce complex proteins in milk, offers a cost-effective and eco-friendly solution to biosimilar production, helping to break down these financial barriers.

"Our BioMilk platform is a game-changer for the biopharmaceutical industry," said Dr. Bertrand Merot, founder and CEO of Bio-Sourcing. "This funding from the EIC Accelerator not only accelerates our mission to make biotherapeutics more affordable but also strengthens Europe's position in the global biopharmaceutical market."

The first biosimilar, adalimumab, a widely used treatment for autoimmune diseases, is expected to generate significant revenue through upfront payments and royalties, fueling further research. Bio-Sourcing plans to bring additional biosimilars to market, including trastuzumab and golimumab, two other major biologics.

Bio-Sourcing’s innovative approach will also contribute to Europe’s biopharmaceutical sovereignty by reducing reliance on external supply chains, an important consideration following recent global health crises. The BioMilk platform not only addresses the challenge of lowering biosimilar production costs but also positions Europe as a leader in sustainable, self-sufficient biomanufacturing.